omniture
logo
Search
广州麓鹏制药有限公司 Guangzhou Lupeng Pharmaceutical Co. LTD
Media Room

Latest News

rss

Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma

GUANGZHOU, China, June 4, 2026 /PRNewswire/ -- Lupeng Pharmaceutical today announced that the Natio...

2026-06-04 16:19 3713

Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL

Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and ...

2026-05-21 22:00 5912